NEOS Investment Management LLC Has $14.20 Million Stake in AstraZeneca PLC $AZN

NEOS Investment Management LLC boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 79.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 185,132 shares of the company’s stock after buying an additional 81,900 shares during the quarter. NEOS Investment Management LLC’s holdings in AstraZeneca were worth $14,203,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. NewSquare Capital LLC boosted its holdings in AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after acquiring an additional 218 shares during the last quarter. Rakuten Investment Management Inc. acquired a new position in shares of AstraZeneca in the 3rd quarter worth approximately $31,000. FSA Wealth Management LLC boosted its stake in shares of AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after purchasing an additional 376 shares during the last quarter. VSM Wealth Advisory LLC bought a new stake in shares of AstraZeneca in the 2nd quarter valued at $33,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its stake in AstraZeneca by 144.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after buying an additional 275 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on AZN. Morgan Stanley reaffirmed an “overweight” rating and set a $103.00 price target on shares of AstraZeneca in a research report on Wednesday, December 3rd. Barclays restated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Wall Street Zen cut AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. HSBC reissued a “buy” rating and issued a $108.00 price target on shares of AstraZeneca in a research note on Wednesday, December 10th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of AstraZeneca in a research report on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average price target of $95.75.

AstraZeneca Stock Up 1.9%

Shares of NASDAQ:AZN opened at $209.39 on Wednesday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. AstraZeneca PLC has a 52-week low of $122.48 and a 52-week high of $211.27. The business’s 50 day simple moving average is $117.40 and its two-hundred day simple moving average is $94.95. The firm has a market cap of $324.74 billion, a P/E ratio of 69.56, a PEG ratio of 1.59 and a beta of 0.34.

AstraZeneca Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be paid a $1.595 dividend. This represents a dividend yield of 165.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s dividend payout ratio (DPR) is 74.83%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.